In December 2023, British American Tobacco wrote down the value of its U.S. cigarette brands — Camel, Newport, Natural American Spirit, and a handful of others — by £25 billion, roughly $31.5 billion. The number was staggering not because it was unexpected but because of what it confessed: that the most storied names in American smoking, brands that had shaped a century of consumer culture, were worth a quarter less than what BAT had paid for them just six years earlier. The write-down itself generated no cash outflow. It moved no inventory. It changed nothing about the 2,500-odd cigarettes rolling off a production line every second at BAT's factories worldwide. What it did was render visible, in the brutally honest language of impairment accounting, the central paradox of the world's second-largest tobacco company: BAT is a business that prints cash from a product category in structural decline, spending that cash to build a future in categories — vapour, heated tobacco, nicotine pouches — where the economics are worse, the regulation is unwritten, and the competitive dynamics are genuinely uncertain. The company's CEO, Tadeu Marroco, described the write-down as a "non-cash charge" and pivoted immediately to the "vast opportunity" of next-generation products. Traders in London were less sanguine. BAT's shares fell to their lowest level in over a decade.
That moment — the collision between legacy profitability and aspirational reinvention — is the story of British American Tobacco. It is a story about what happens when an industry's greatest asset, the addictive loyalty of its customer base, begins to erode not because customers quit nicotine but because they find new ways to consume it. It is a story about consolidation as strategy, about the paradox of a company that grew by acquiring competitors only to discover that the most dangerous competitor was a technology shift rather than a rival brand. And it is, at its deepest level, a story about the strange economics of decline — about whether a business generating over £3 billion in annual free cash flow can reinvent itself fast enough to matter, or whether it is destined to become the most profitable obituary in corporate history.
By the Numbers
The BAT Empire, 2025
£13.4BH1 2025 revenue (annualized ~£26.8B)
42.0%Reported operating margin, H1 2025
30.5MConsumers of smokeless products
18.2%Smokeless share of Group revenue, H1 2025
180+Countries where products are sold
~46,000Employees worldwide (est.)
£1.1B2025 share buyback programme
$31.5B2023 U.S. brand impairment charge
The Machine James Duke Built
The origin of British American Tobacco is inseparable from the origin of the modern cigarette industry itself, and both are inseparable from a single figure: James Buchanan Duke. Born in 1856 near Durham, North Carolina, Duke was the son of a modest tobacco farmer who returned from the Civil War to find his crop — unlike his neighbors' cotton — still possessed commercial value. The young Duke learned the trade by hand-packing smoking tobacco into muslin bags, but his ambition ran on an industrial scale. He was not interested in artisanal production. He was interested in machines.
In the mid-1880s, Duke licensed the Bonsack cigarette-rolling machine, a device that could produce 120,000 cigarettes per day — roughly thirty times the output of a skilled hand-roller. The economics were transformative. Duke's cost per thousand cigarettes plummeted, and he deployed the savings into something the tobacco industry had never seen at such scale: national advertising. Cigarette cards, billboards, newspaper ads, cross-promotions. By 1890, Duke's firm, W. Duke Sons & Company, had driven its competitors to the negotiating table, and the resulting merger created the American Tobacco Company — a trust that controlled, at its peak, roughly 90% of U.S. cigarette production. Duke was 33.
The parallels to later platform monopolies are uncanny: a technological cost advantage (the Bonsack machine), deployed through a marketing flywheel (advertising funded by unit-cost savings), consolidated through M&A (the trust), and eventually broken apart by antitrust action. In 1911, the U.S. Supreme Court ordered the dissolution of the American Tobacco Company under the Sherman Act, splitting it into several successor firms — among them the American Tobacco Company (reconstituted), R.J. Reynolds, Liggett & Myers, and Lorillard. But Duke's international ambitions had already been spun off a decade earlier.
In 1902, Duke's American Tobacco Company and Britain's Imperial Tobacco — itself a defensive merger of thirteen British firms alarmed by Duke's expansion into the UK market — reached a truce. The terms were elegant in their cartel logic: Imperial would stay out of America, American Tobacco would stay out of Britain, and a jointly owned new entity, the British-American Tobacco Company, would handle the rest of the world. That entity — BAT — was born not from entrepreneurial vision but from competitive stalemate, a negotiated partition of global markets between two powers that had fought each other to exhaustion. Howard Cox's
The Global Cigarette: Origins and Evolution of British American Tobacco remains the definitive account of this formation, and what it reveals is that BAT's DNA was, from the start, fundamentally different from its American counterparts. It was built to be international. Its home markets were everywhere and nowhere.
🏛
The Dissolution and Its Children
Key entities born from the 1911 breakup of Duke's tobacco trust
1890James B. Duke merges five firms to create the American Tobacco Company, controlling ~90% of U.S. cigarette output.
1902American Tobacco and Imperial Tobacco form British-American Tobacco Company to manage all markets outside the U.S. and UK.
1911U.S. Supreme Court orders dissolution of the American Tobacco trust; successor companies include American Tobacco, R.J. Reynolds, Liggett & Myers, and Lorillard.
1912BAT becomes a fully independent, London-listed company as its parent entities divest their stakes following the antitrust ruling.
This origin matters because it explains something about BAT that persists to this day: the company has always been defined by geography more than by brand. Where Philip Morris built Marlboro into the world's most valuable cigarette brand — a single icon deployed globally — BAT assembled a portfolio of regional brands, adapting to local tastes, regulatory regimes, and distribution networks across more than 180 countries. Dunhill in Asia and Europe, Lucky Strike in parts of Latin America and Europe, Pall Mall as a global value play, Kent in Eastern Europe and Japan. The strategy was less Coca-Cola — one brand, one message, everywhere — and more Unilever: a federation of local champions under a corporate umbrella. This structure made BAT resilient to any single-market disruption. It also made it harder to build the kind of unified brand equity that Philip Morris enjoyed with Marlboro.
A Century of Addictive Cash Flows
The economics of cigarettes are, from a pure business standpoint, almost obscenely attractive. The product is small, light, inexpensive to manufacture, and consumed at a rate of roughly 20 units per day by a habitual user. Nicotine's pharmacological properties create one of the most reliable demand curves in consumer goods: once acquired, the customer rarely churns voluntarily. Price elasticity is low — studies consistently show that a 10% increase in cigarette prices reduces consumption by only 3–5% in developed markets, and even less in emerging ones. Gross margins in cigarette manufacturing run above 60%; operating margins for the major tobacco companies regularly exceed 40%.
BAT has ridden these economics for over a century. The company's path through the twentieth century was one of geographic expansion into markets that Philip Morris — focused primarily on the United States and Western Europe — underserved. BAT was in China before the revolution, in India through its associate company ITC (in which it still holds a roughly 29% stake worth billions), across sub-Saharan Africa, throughout Southeast Asia. When one market became hostile — nationalization in China in the 1950s, for instance — others were growing.
The critical feature of the tobacco business model, beyond its individual-level stickiness, is the industry's oligopolistic structure. After a century of consolidation, four companies — Philip Morris International (PMI), BAT, Japan Tobacco International (JTI), and Imperial Brands — control approximately 70% of global cigarette volumes (excluding China, where the state monopoly CNTC dominates). This concentration produces pricing discipline. When volumes decline, the surviving players raise prices, and total revenue often grows even as unit sales shrink. The cigarette business does not behave like a normal declining industry; it behaves like a toll road whose traffic is gently falling but whose tolls are steadily rising.
Richard Kluger's Pulitzer Prize-winning
Ashes to Ashes: America's Hundred-Year Cigarette War captures the industry's peculiar relationship with its own mortality: decades of litigation, regulation, advertising bans, and public health campaigns have not destroyed the business. They have, in a perverse way, strengthened it — by raising barriers to entry so high that no new competitor can realistically challenge the incumbents, and by making it socially unacceptable to advertise, which means the existing brands are effectively frozen in place. The regulatory moat, in tobacco, is arguably deeper than the brand moat.
Our smokeless portfolio now accounts for 18.2% of Group revenue, an increase of 70 bps vs FY24. I am very pleased with our performance in the U.S. Revenue and profit are both up for the first time since 2022.
Consolidation as Destiny
If BAT's first century was about geographic expansion, its second act has been about consolidation — assembling, through a series of increasingly large acquisitions, the scale needed to survive an industry whose volumes decline by 2–3% annually in developed markets. The logic is straightforward: in a shrinking industry, the last player standing captures a disproportionate share of the remaining profit pool. Every acquisition that adds brands, distribution, and pricing power is an investment in longevity.
The modern era of BAT deal-making began in 1999, when the company acquired Rothmans International for $7.5 billion. Rothmans, controlled by South Africa's billionaire Rupert family, brought together the second- and fourth-largest tobacco companies in the world. The deal added brands like Dunhill and Rothmans to BAT's portfolio and deepened its presence in Africa and Asia. It was, in the language of the industry, a "formidable rival to Philip Morris."
But the deal that defined BAT's strategic trajectory — and created the $31.5 billion impairment — came almost two decades later. In January 2017, BAT announced its intention to acquire the remaining 57.8% of Reynolds American Inc. (RAI) that it did not already own, in a transaction valued at approximately $49 billion. The merger agreement, filed with the SEC on January 16, 2017, specified that RAI shareholders would receive 0.5260 of a BAT American Depositary Share plus $29.44 in cash per share. The deal closed in July 2017. BAT had been a 42.2% shareholder of Reynolds since 2004 — itself the product of the merger between R.J. Reynolds and Brown & Williamson, BAT's former U.S. subsidiary — and the full acquisition was both strategically logical and financially staggering.
The logic: BAT gained full ownership of Camel, Newport (the best-selling menthol cigarette in America), Natural American Spirit, and Pall Mall's U.S. operations — plus Reynolds's growing Vuse e-cigarette brand. The U.S. is the world's most profitable cigarette market by a wide margin, with per-pack prices and margins roughly double those in most other geographies. Owning the #2 U.S. player outright (behind Altria/Philip Morris USA) gave BAT access to that profit pool in a way its international portfolio never could.
The cost: BAT took on approximately $45 billion in acquisition-related debt. The company's bond offerings tell the story of an enterprise borrowing at scale — a $17.25 billion multi-tranche offering in 2017 alone, with notes maturing as far out as 2047. The 2018 424B3 SEC filing reveals the breadth: $2.25 billion in 2.297% notes due 2020, $3.5 billion in 3.557% notes due 2027, $2.5 billion in 4.540% notes due 2047. The cost of capital was cheap by historical standards — this was still the era of low interest rates — but the absolute quantum of debt was transformative. BAT went from a conservatively financed international tobacco company to one of the most leveraged consumer goods businesses on the planet.
BAT's $49 billion acquisition of Reynolds American, 2017
| Metric | Detail |
|---|
| Transaction value | ~$49 billion (for 57.8% not already owned) |
| Per-share consideration | 0.5260 BAT ADSs + $29.44 cash |
| Key brands acquired | Camel, Newport, Natural American Spirit, Pall Mall (U.S.), Vuse |
| Debt raised | ~$17.25 billion in multi-tranche bond offerings (2017) |
| Pre-existing stake | 42.2% of RAI (held since 2004) |
| Closing date | July 25, 2017 |
And then the world changed. U.S. cigarette volumes, already in secular decline, accelerated their descent. Illicit vapes — cheap, disposable, often manufactured in Shenzhen — flooded the American market, pulling younger smokers away from traditional cigarettes faster than anyone modeled. By 2023, BAT was acknowledging that its U.S. sales had "slipped," driven partly by what it called "illicit" vaping products. The brands BAT had paid $49 billion to control were eroding not because consumers stopped craving nicotine but because they found cheaper, more convenient, less stigmatized ways to get it.
The December 2023 impairment was the accounting reckoning. But the strategic reckoning had been building for years.
The Name That Tells the Story
There is something clarifying about the name itself. British American Tobacco. It tells you, in three words, everything about the company's structural identity: a British-headquartered, American-exposed, tobacco-dependent enterprise. The "British" part means London listing, sterling reporting currency, and a corporate governance framework shaped by UK norms — including a unitary board with independent directors and an approach to shareholder engagement more restrained than American norms. The "American" part, since 2017, means that a majority of the company's profit comes from a single national market — the United States — where regulatory risk is concentrated in the FDA, litigation risk is a permanent background condition, and the competitive landscape is dominated by the Altria/PMI duopoly. The "Tobacco" part is both the company's greatest asset and its existential constraint: BAT cannot become a technology company, a healthcare company, or a consumer goods conglomerate. It is, irreducibly, a nicotine delivery company. The question is only which delivery mechanisms will dominate.
The Colossus Business Breakdowns podcast with Evan Tindell of Bireme Capital captured this tension precisely: the dynamics of international versus domestic are "truly unique in this market." BAT's pre-2017 business was geographically diversified but U.S.-underweight. The Reynolds acquisition made it U.S.-heavy — and therefore concentrated in the market where combustible decline was sharpest, illicit vape competition was most intense, and the regulatory apparatus was most unpredictable.
The Nicotine Migration
Tadeu Marroco, who became CEO in May 2023 after serving as BAT's Chief Financial Officer, inherited a company in the middle of the most significant product transition in the tobacco industry's history. Marroco — a Brazilian-born finance professional who spent over two decades at BAT in various roles across the globe — brought a CFO's discipline to a challenge that was fundamentally entrepreneurial: how to reallocate capital from a high-margin, declining business to a lower-margin, growing one without destroying shareholder value in the process.
The transition has a name inside BAT: "New Categories." These are vapour (Vuse), tobacco heating products (glo), and modern oral nicotine (Velo). The company's stated ambition, articulated repeatedly by Marroco and his predecessor Jack Bowles, is to build a "smokeless world" — a phrase that is simultaneously aspirational brand positioning and strategic necessity. By H1 2025, smokeless products accounted for 18.2% of Group revenue, up 70 basis points from full-year 2024. BAT had accumulated 30.5 million consumers of its smokeless brands, adding 1.4 million in the first half of 2025 alone.
The economics of the shift, though, are unforgiving. Combustible cigarettes carry operating margins north of 40%. New Categories, while growing, operate at significantly lower margins — the products require heavier R&D spend, more capital-intensive manufacturing, and aggressive consumer acquisition spending. Vapour devices are electronic hardware with a shorter replacement cycle and more competitive alternatives. Heated tobacco (glo) competes against Philip Morris International's IQOS, which dominates the category globally. Nicotine pouches (Velo) are the brightest spot — the fastest-growing New Category — but face intensifying competition from Swedish Match (now owned by PMI) and a flood of independent brands.
Smokers are changing fast, and so are we.
In the UK, BAT's own operations illustrate the speed of the migration. Asli Ertonguc, managing director of BAT's UK and Irish operations, disclosed in October 2025 that vaping and nicotine pouches had surged to make up nearly 70% of the company's UK revenue in just five years. That figure is startling — it suggests that in at least one major developed market, the combustible-to-smokeless transition is not a gradual evolution but a step-function change. The question is whether BAT can monetize this transition as effectively as it monetized combustibles, or whether the shift to lower-margin, more competitive product categories will permanently compress returns.
The Debt Overhang
The Reynolds acquisition loaded BAT's balance sheet with debt at precisely the moment when the company needed financial flexibility to invest in New Categories. The $17.25 billion in bonds issued in 2017 was just the beginning. Subsequent refinancings and new issuances have kept BAT as a frequent visitor to the debt capital markets. In March 2025, B.A.T Capital Corporation priced another $2.5 billion in notes — $1 billion at 5.350% due 2032, $1 billion at 5.625% due 2035, and $500 million at 6.250% due 2055 — with proceeds directed to "general corporate purposes, including the potential repayment of existing indebtedness." In September 2025, another $750 million at 4.625% due 2033.
The interest rates tell a story of their own. The 2017 notes were issued at rates between 2.297% and 4.540%. The 2025 notes are priced at 4.625% to 6.250%. BAT is refinancing cheap debt with expensive debt, in an environment where its underlying cash flows are growing modestly at best. The company's deleveraging trajectory — management has repeatedly committed to reducing net debt/EBITDA — is real but slow, constrained by the simultaneous demands of debt service, dividend payments (BAT has historically yielded 7–9% to shareholders), share buybacks (£1.1 billion announced for 2025), and New Category investment.
The notes themselves are guaranteed on a senior, unsecured basis by a cascade of BAT entities — British American Tobacco p.l.c., B.A.T. International Finance p.l.c., B.A.T. Netherlands Finance B.V., and Reynolds American Inc. The guarantee structure means that the Reynolds subsidiary, the very asset whose impairment shocked the market in 2023, remains a credit backstop for the parent's debt. It is a structural reminder that BAT and Reynolds are now inseparable — for better and for worse.
The Factory Floor as Strategic Frontier
One dimension of BAT that receives insufficient attention is its manufacturing complexity. This is a company operating more than 40 factories worldwide, producing products that range from hand-rolled cigarettes in emerging markets to precision-engineered vaping devices that are, in effect, consumer electronics. The operational challenge of straddling these two worlds — artisanal tobacco production and high-tech nicotine delivery — is enormous.
BAT's partnership with Amazon Web Services offers a window into this transition. By 2024, the company had migrated approximately 80% of its workloads to the cloud, with a target of 95–98%. But factory systems — manufacturing execution systems, supervisory control and data acquisition (SCADA) systems, programmable logic controllers connected to robotic devices — are exquisitely sensitive to latency. A few extra milliseconds of delay between a cloud server and a production-line robot can disrupt an entire factory run. BAT deployed AWS Outposts — hybrid cloud infrastructure that runs AWS services on-premises — at a pilot factory in Mexico, migrating 13–15 critical systems including its global MES and inventory tracking systems for government regulators. The deployment achieved 1–3 millisecond network latency and 45% cost savings.
The detail matters because it reveals something about BAT's strategic posture: this is not a company content to simply harvest its declining combustible business. The cloud migration, the factory modernization, the digital infrastructure investment — these are the moves of a company that believes it will be manufacturing complex products at scale for decades to come. Whether those products are cigarettes, heated tobacco sticks, or next-generation vaping devices, the manufacturing platform is being rebuilt. The $31.5 billion write-down was an accounting event. The factory floor investment is an operational bet.
The ITC Card
BAT holds approximately 29% of ITC Limited, one of India's largest conglomerates. ITC began as Imperial Tobacco Company of India — a BAT subsidiary — and over the decades diversified into hotels, FMCG, paperboard, and agribusiness, becoming one of the most widely held stocks on the Indian exchanges. BAT's stake, worth billions of dollars, is both a strategic asset and a source of capital flexibility.
In 2025, BAT partially monetized its ITC holding — Marroco referenced the "recent partial monetisation of our ITC stake" as having "enhanced our capital flexibility" in the H1 2025 results. The ITC stake functions as a kind of strategic reserve: a liquid, valuable asset that can be sold down to fund debt repayment, share buybacks, or New Category investment without touching the operating business. It is, in a sense, the inheritance from BAT's imperial past — a century-old colonial-era investment that now subsidizes the company's digital-age reinvention.
The Illicit Shadow
The rise of illicit vapes — unregulated, untaxed, often manufactured in China — represents a category of competitive threat that BAT has never faced in its combustible business. In combustibles, the barriers to entry are immense: you need tobacco leaf supply chains, manufacturing at scale, distribution agreements with retailers, and regulatory approvals that take years to secure. The illicit cigarette market exists but is largely confined to smuggling and counterfeiting, and the major companies have sophisticated enforcement operations to combat it.
Vaping is different. A disposable vape is a battery, a heating element, a tank of nicotine liquid, and a microchip. The manufacturing cost is low. The supply chain is global and fast. And the regulatory frameworks in most countries are still being built, creating a grey zone in which unlicensed products can flood markets before enforcement catches up. BAT has cited illicit vapes as a significant factor in its U.S. volume declines. The company's response has been multi-pronged: lobbying for stricter enforcement against unlicensed products, investing in its own Vuse brand to compete on quality and availability, and — in the UK — advocating for a "very strict marketing framework" that would allow regulated vape companies to advertise to adult smokers.
The irony is rich. For a century, Big Tobacco's moat was partly constructed by the very regulations designed to constrain it. Advertising bans froze incumbent brand positions. Excise taxes raised consumer switching costs.
Distribution regulations made it nearly impossible for new entrants to reach shelves. Now, in the vaping market, the absence of mature regulation is creating the opposite dynamic: low barriers to entry, rampant competition, and a flood of products that undercut the incumbents on price.
BAT's UK managing director Ertonguc put it plainly: the company wants tighter regulation of vaping, not less. The proposed UK Tobacco and Vapes Bill, which would ban vape advertising entirely and require retail licences for sales, would — if BAT's thesis is correct — disproportionately harm the illicit operators while strengthening the incumbents' position. It would, in effect, rebuild the regulatory moat in the new category. Whether governments will oblige is another question.
The Canadian Reckoning
BAT's Canadian subsidiary has been the subject of a settlement provision — repeatedly referenced in financial results with the careful qualifier "as adjusted for Canada" — relating to historical tobacco litigation. The Canadian legal landscape for tobacco companies has been uniquely punitive: in 2015, a Quebec court ordered three tobacco companies, including BAT's subsidiary Imperial Tobacco Canada, to pay a combined C$15.5 billion in damages in a landmark class-action lawsuit. The litigation and its associated provisions have been a persistent drag on BAT's reported earnings, requiring the company to present its financials both with and without the Canadian impact.
In H1 2025, BAT reported an update to the Canadian settlement provision that partly contributed to a 19.1% increase in reported profit from operations. The episode illustrates a structural feature of the tobacco business that investors sometimes underweight: litigation risk is not a one-time event but a recurring cost of doing business, embedded in the financial structure of every major tobacco company. The Canadian experience is the most acute expression of a risk that exists — in varying degrees of severity — across every jurisdiction where BAT operates.
A [Quality](/mental-models/quality) Growth Thesis
Marroco has articulated a framework he calls "Quality Growth" — a phrase that appears repeatedly in BAT's 2025 communications. The idea is deceptively simple: instead of pursuing volume growth across all geographies and categories, concentrate investment in the largest profit pools and the highest-return opportunities. In practice, this means prioritizing the U.S. market (where margins are highest), investing selectively in Velo and Vuse (where growth is strongest), and managing the combustible portfolio for cash flow rather than volume.
The H1 2025 results offered the first tangible evidence that this approach is working. U.S. revenue and profit were both up for the first time since 2022 — a milestone that reflects both improved combustible performance (BAT's volume and value share returned to growth) and the successful launch of Velo Plus, a next-generation nicotine pouch. AME (Africa, Middle East, and Europe) continued to grow. APMEA (Asia Pacific, Middle East, and Asia) was challenged by "fiscal and regulatory challenges in Bangladesh and Australia."
The overall picture: reported revenue down 2.2% due to currency headwinds, but up 1.8% at constant exchange rates. Adjusted profit from operations (as adjusted for Canada) up 1.9% at constant currency. Adjusted operating margin flat at 43.2%. Reported diluted EPS up 1.6% to 203.6p. Not explosive growth. Not decline. A business that is managing its transition with the financial discipline of a company that cannot afford to get it wrong.
Marroco's confidence is measured but explicit: "I am committed to delivering sustainable value for our shareholders." The share buyback programme was increased by £200 million to £1.1 billion. The implicit message: the stock is cheap, the cash flows are real, and management believes the market is mispricing the company's prospects.
I am confident that the investments we have made and actions we are taking, will drive a return to our mid-term algorithm in 2026.
The Pouch That Could Save the Empire
If any single product category could justify BAT's reinvention thesis, it is nicotine pouches. Velo — BAT's brand in the category — is a small, white pouch containing synthetic or tobacco-derived nicotine, placed between the lip and gum. No smoke. No vapour. No device. No charging. No social stigma. The user experience is discreet, the product profile is simple, and the regulatory landscape is — for now — more permissive than vaping in many jurisdictions.
The category is exploding. In the United States, nicotine pouch volumes have been growing at double-digit rates annually, driven by Zyn (owned by PMI through its acquisition of Swedish Match) and Velo. BAT launched Velo Plus in the U.S. in 2025, a next-generation product designed to compete more directly with Zyn on flavor, nicotine delivery, and consumer experience. The early results, according to BAT's H1 2025 report, are encouraging — Velo contributed to the return to U.S. growth that Marroco highlighted.
The strategic appeal of pouches, from BAT's perspective, is that they combine the attractive features of combustibles (habitual use, high margins, simple manufacturing) with the growth trajectory of New Categories. Unlike vaping devices — which are essentially consumer electronics with all the associated R&D complexity, battery safety issues, and competitive dynamics — pouches are a packaged goods product. They can be manufactured at scale using existing tobacco supply chain expertise. They don't require Bluetooth connectivity or firmware updates. They are, in a sense, the nicotine delivery mechanism most compatible with BAT's century-old operational DNA.
The risk is that PMI, through Zyn, has a substantial head start. Zyn is the category leader in the U.S. by a wide margin, and Swedish Match's manufacturing capacity has been expanded aggressively since the PMI acquisition. BAT is playing catch-up in the fastest-growing New Category — a position it is not accustomed to.
Smoke and Mirrors in the Mirror
The tobacco industry has always had a complicated relationship with truth. For decades, the major companies denied what their own scientists knew: that smoking caused cancer, that nicotine was addictive, that their marketing targeted young people. The 1994 congressional testimony — seven CEOs, each raising a right hand, each testifying under oath that they did not believe nicotine was addictive — remains one of the most iconic images of corporate dishonesty in American history. The subsequent litigation, culminating in the 1998 Master Settlement Agreement in the U.S. and similar accords globally, reshaped the industry's relationship with regulators, the public, and its own narrative.
BAT's version of this history is global in scope. Investigative reporting has documented allegations of corrupt practices — bribery, smuggling facilitation, manipulation of scientific research — across multiple jurisdictions and decades. The company's present-day messaging — "Building a Smokeless World," "Creating a Better Tomorrow" — carries an inherent tension. It asks stakeholders to believe that the company which spent the twentieth century denying the harm of its products is now genuinely committed to reducing that harm. Whether this represents authentic corporate transformation or sophisticated brand management is a question that each observer must answer for themselves.
What is not in question is the financial imperative. BAT does not pursue harm reduction because it is nice. It pursues harm reduction because the alternative — clinging to combustibles as the customer base literally dies — is corporate suicide on a 30-year timeline. The smokeless transition is an existential necessity disguised as a moral awakening.
The Price of Persistence
In the tobacco industry, the penalty for failure is not bankruptcy. It is irrelevance. The cigarette business will generate cash flows for decades to come — even in the worst-case scenario, there will be smokers in 2050, and someone will be selling them cigarettes. The question is whether BAT, specifically, will be the company that captures the nicotine consumer of 2035 — the consumer who uses a pouch, a vape, a heated tobacco stick, or some delivery mechanism not yet invented — or whether it will be a cash-flow harvesting operation, slowly returning capital to shareholders as its brands fade.
Marroco's "Quality Growth" framework is, at its core, a bet on the former. The £1.1 billion share buyback says the stock is undervalued. The Velo Plus launch says the company can compete in New Categories. The partial ITC monetisation says there are assets to unlock. The cloud migration and factory modernization say the operational platform is being future-proofed. The 43.2% adjusted operating margin says the combustible engine is still running, still funding the reinvention.
Against this: the $31.5 billion write-down says the market got repriced faster than expected. The debt load says financial flexibility is constrained. The illicit vape market says competitive dynamics in New Categories are fundamentally different from combustibles. The Zyn juggernaut says BAT is behind in the category that matters most. The Canadian litigation says the past never stops billing.
And beneath all of it, a number: 30.5 million consumers of BAT's smokeless products, as of mid-2025. Up from zero a decade ago. The empire is being rebuilt, one pouch and one vape at a time, in the shadow of the old one. Whether 30.5 million becomes 100 million or plateaus at 50 million — whether the margins converge toward combustible economics or settle permanently lower — is the question that the next decade will answer.
On the factory floor in Mexico, a manufacturing execution system runs on AWS Outposts, managing production orders for products that will be shipped to consumers who have never lit a match. The latency is 1–3 milliseconds. The cost savings are 45%. The machines don't know what they're making. They just know not to stop.
